The mechanisms of lung microvascular complications and pulmonary hypertension known to be associated with idiopathic pulmonary fibrosis (IPF), a debilitating lung disease, are not known. Therefore, we investigated whether bleomycin, the widely used experimental IPF inducer, would be capable of activating phospholipase D (PLD) and generating the bioactive lipid signalmediator phosphatidic acid (PA) in our established bovine lung microvascular endothelial cell (BLMVEC) model. Our results revealed that bleomycin induced the activation of PLD and generation of PA in a dose-dependent (5, 10, and 100 mg) and timedependent (2-12 hours) fashion that were significantly attenuated by the PLD-specific inhibitor, 5-fluoro-2-indolyl deschlorohalopemide (FIPI). PLD activation and PA generation induced by bleomycin (5 mg) were significantly attenuated by the thiol protectant (N-acetyl-L-cysteine), antioxidants, and iron chelators suggesting the role of reactive oxygen species (ROS), lipid peroxidation, and iron therein. Furthermore, our study demonstrated the formation of ROS and loss of glutathione (GSH) in cells following bleomycin treatment, confirming oxidative stress as a key player in the bleomycin-induced PLD activation and PA generation in ECs. More noticeably, PLD activation and PA generation were observed to happen upstream of bleomycin-induced cytotoxicity in BLMVECs, which was protected by FIPI. This was also supported by our current findings that exposure of cells to exogenous PA led to internalization of PA and cytotoxicity in BLMVECs. For the first time, this study revealed novel mechanism of the bleomycininduced redox-sensitive activation of PLD that led to the generation of PA, which was capable of inducing lung EC cytotoxicity, thus suggesting possible bioactive lipid-signaling mechanism/mechanisms of microvascular disorders encountered in IPF.
Introduction
Cellular membranes consist of phospholipids, proteins, and carbohydrate moieties. The membrane phospholipids are critical for the cellular homeostasis and survival at the levels of both the cell structure and function. Cellular signaling is one of the crucial cell functions required for homeostasis. Phospholipase D (PLD) is an important membrane phospholipid hydrolase, which generates a potent cellular bioactive lipid signal mediator, phosphatidic acid (PA) that is further metabolized into potent bioactive lipid signal mediators such as diacylglycerol (DAG) and lysophosphatidic acid (LPA). [1] [2] [3] PLD has been shown to be involved in several pathophysiological conditions such as cardiovascular diseases and cancer. 4, 5 Thus, the PLD-generated bioactive lipid mediators (PA, DAG, and LPA) regulate the cellular cytoskeleton, especially the actin cytoskeleton, which leads to the regulation and/or alteration of the cell shape and movement.
Phospholipase D activation in mammalian cells is under the control of several regulators including hormones, growth factors, G protein-coupled receptors, and other bioactive signal mediators through the regulation of protein kinases such as protein kinase C (PKC), tyrosine kinase, and mitogen-activated protein kinases. 1 Oxidative stress and oxidant exposure (reactive oxygen species [ROS] ) are known to activate PLD in mammalian cells. 6 Vascular endothelial cells (ECs), the inner monolayer lining of blood vessels which form the barrier, are susceptible to oxidative stress that leads to vascular EC disruption and vascular leak. It is emerging that oxidative stressinduced activation of PLD and associated lipid-signaling enzymes are among key responsible players in EC dysfunction, leading to pathophysiological conditions in lung vasculature during oxidant exposure such as infection, pulmonary hypertension (PH), lung fibrosis, and hyperoxic lung damage. Oxidative stress also leads to redox perturbation in vascular ECs such as alterations in the soluble thiols (glutathione [GSH] ) and protein thiols. 2 However, the thiol redox modulation of oxidative stress-mediated activation of PLD in lung ECs is not completely understood. Therefore, here, it is envisioned that oxidative stress causes an imbalance in the thiol redox of the lung vascular ECs so that the redox-sensitive PLD is activated, resulting in the generation of the bioactive lipid mediator, PA, that ultimately signals the vascular EC dysfunction and damage.
Idiopathic pulmonary fibrosis (IPF) is a degenerative, chronic, and progressive fibrosing lung disorder of the tissue that lines and separates the alveoli with unknown etiology for which the mechanisms of the onset and progression of the disease are not thoroughly understood. 7 The prevalence of IPF in the United States is estimated in the range of 35 000 to 55 000 cases as recorded in 2005. 8 Extended exposure to environmental and occupational agents including metal, wood, and stone dusts has been associated with the tissue damage that leads to IPF among the idiopathic lung diseases. 9, 10 In IPF, the tissue that lines and separates the alveoli becomes scarred due to lung damage. This scarring causes the tissue to become inelastic and hard. The buildup of scar tissue causes difficulties in breathing and results in respiratory failure. Interstitial lung diseases (ILDs) including the sarcoidosis, IPF, and pulmonary Langerhans cell histiocytosis have been shown to be associated with PH. 11, 12 Lung parenchymal and vascular remodeling indicates the high prevalence (30%-40%) of PH among the ILD patients. 13 Although both the lung epithelium and endothelium have been shown to be the critical cellular players in IPF, microvascular injury has been shown as an initial event in lungs during IPF. 14 In addition, microvascular injury has been emphasized as an important event in the evolution of IPF. 15 Therefore, the lung microvasculature, specifically the lung microvascular endothelium is apparently an important target in the lung fibrotic events. This offers a premise to hypothesize that lung microvasculature is a key player in the mechanism of onset/progression of IPF.
Several cellular signaling mechanisms involving caveolae, caveolins, protein kinases, focal adhesion kinase, protein kinase B, and mitogen-activated protein kinases (MAPKs) have been shown to operate in the IPF. [16] [17] [18] Studies with experimental models have revealed the role of oxidative stress and antioxidant imbalance in the initiation and progression of IPF, and accordingly redox modulatory therapy has been proposed for the treatment of the disease. 7, 19 The lung microvasculature and vascular endothelium are critical regions in IPF, oxidative stress and redox alterations appear to drive the initiation and progression of IPF. Oxidants are known to activate the lung vascular endothelial PLD, leading to the generation of bioactive lipid mediators. Therefore, it is compelling to rationalize that oxidant-mediated lung microvascular endothelial PLD signaling is likely to play a crucial role in the initiation and propagation of IPF. To date, no reports have been made on the activation of PLD by the experimental lung fibrosis inducer, bleomycin, in lung cells including the vascular endothelium. Therefore, here, we have hypothesized that bleomycin induces oxidant-mediated and redox-dependent PLD activation upstream that leads to the downstream cytotoxicity through the PLD-generated bioactive lipid mediator, PA in the lung microvascular ECs in culture. In order to test this hypothesis, we used the well-established bovine lung microvascular ECs (BLMVECs) and exposed them to the experimental lung fibrosis inducer, bleomycin, to establish the thiol redox regulation of PLD activation in lung ECs and define the connection between the upstream PLD activation and downstream cytotoxicity that could be responsible for the oxidant-mediated lung vascular dysfunction similar to that encountered in IPF conditions. In order to investigate the comparative responses to bleomycin treatment exhibited by another lung microvascular EC model, we also included the well-established human lung microvascular ECs (HLMVECs) in the current study. For the first time, the results of the current study revealed that the experimental lung fibrosis inducer, bleomycin, caused the upstream activation of PLD and generated the bioactive lipid signal mediator, PA, in oxidant-mediated and redox-sensitive mechanism that led to the cytotoxicity in the lung microvascular ECs in culture, suggesting the possible role of PLD in IPF.
Materials and Methods Materials
Bovine lung microvascular ECs (passage 4) were purchased from VEC Technologies (New York). Phosphate-buffered saline (PBS) was obtained from Biofluids Inc (Rockville, Maryland). Human lung microvascular ECs and endothelial growth medium-2-microvascular ([EGM-2-MV] containing 5% fetal bovine serum [FBS], hydrocortisone, human recombinant vascular endothelial growth factor, recombinant human fibroblast growth factor-B, recombinant insulin-like growth factor 1, human recombinant epidermal growth factor, ascorbic acid, gentamycin, and amphotericin-B) were purchased from ProCell GmbH (Heidelberg, Germany). Minimal essential medium (MEM), nonessential amino acids, trypsin, FBS, penicillin/streptomycin, Dulbecco modified Eagle medium (DMEM) phosphatefree modified medium, tissue culture reagents, 3-[4,5dimethylthiazol-2-yl]-2, 5-diphenyl tetrazolium bromide reduction kit (MTT assay kit), lactate dehydrogenase cytotoxicity assay kit (LDH release assay kit), and analytical reagents of highest purity were all purchased from Sigma Chemical Co (St Louis, Missouri). Phosphatidylbutanol (PBt), fluorescent C 6:0-18:1 NBD-PA, 1-oleoyl-2-{6-[(7-nitro-2-1, 3-benzoxadiazol-4-yl) amino]hexanoyl}-sn-glycero-3-phosphate (C 18:2 PA), and 1palmitoyl-2-oleoyl-sn-glycero-3-phosphate (C 16:0-18:1 PA) were obtained from Avanti Polar Lipids (Alabaster, Alabama). [ 32 P]orthophosphate (carrier-free) was obtained from New England Nuclear (Wilmington, Delaware). Bleomycin was obtained from Teva Parenteral Medicines (Irvine, California). Desferal was obtained from Calbiochem (San Diego, California). Polyclonal antibody raised against 4-hydroxy-2-nonenal (anti-HNE) was obtained from Enzo Life Sciences (Farmingdale, New York). Endothelial cell growth factor was obtained from Upstate Biotechnology (Lake Placid, New York). Antirabbit AlexaFluor 488-conjugated antibody and 4 0 ,6diamidino-2-phenylindole dihydrochloride (DAPI) were purchased from Molecular Probes Invitrogen Co (Carlsbad, California). 5-Fluoro-2-indolyl des-chlorohalopemide hydrochloride hydrate (FIPI) was prepared as described earlier. 5, 20, 21 Glutathione assay kit (GSH-Glo) was obtained from Promega Corporation (Madison, Wisconsin).
Cell Culture
Bovine lung microvascular ECs were grown to confluence in MEM supplemented with 10% (vol/vol [v/v]) FBS, 100 units/ mL penicillin and streptomycin, 5 mg/mL EC growth factor, and 1% (v/v) nonessential amino acids at 37 C under a humidified 95% air and 5% CO 2 atmosphere, as described earlier. 1 Bovine lung microvascular ECs, from passages 7 to 15, were used in the experiments. Human lung microvascular ECs were cultured in the EGM-2-MV medium under a humidified 95% air and 5% CO 2 atmosphere. Human lung microvascular ECs, from passages 2 to 6, were used in the experiments. Endothelial cells cultured in 35-mm or 60-mm sterile dishes or T-75 cm sterile flasks to *95% confluence under a humidified 95% air and 5% CO 2 atmosphere were used for treatments with bleomycin and desired pharmacological agents. Minimal essential medium containing bleomycin and other pharmacological agents were carefully adjusted to pH 7.4 for cellular treatments.
Phospholipase D Activation in Intact ECs
Phospholipase D activity in ECs was determined according to our previously published procedure. 1, 2, 6 Endothelial cells in 35-mm dishes (5 Â 10 5 cells/dish) were labeled with [ 32 P]orthophosphate (5 mCi/mL) in DMEM phosphate-free medium containing 2% (v/v) FBS for 6 to 14 hours. 6 Following experimental treatments, [ 32 P]-labeled phosphatidylbutanol ([ 32 P]PBt) formed from PLD activation and transphosphatidylation reaction in cellular lipid extracts, as an index of PLD activity in intact cells, was separated by thin-layer chromatography (TLC). 1, 6 Radioactivity associated with the [ 32 P]PBt was quantified by liquid scintillation counting, and data were expressed as Disintegrations per minute (DPM) normalized to 10 6 counts in the total cellular lipid extract or as percentage of control (vehicle-treated cells).
Phosphatidic Acid Formation in Intact ECs
At the end of the experiments, treatments of cells were terminated by the addition of 1 mL methanol:HCl (100:1, v/v). Lipids were extracted essentially according to the method of Bligh and Dyer, as described previously. 1 [ 32 P]-labeled PA formed from PLD activation, as an index of PLD activity in intact cells, was separated by TLC. 1, 6 Autoradiogram was developed from the TLC plate with [ 32 P]PA separated from other phospholipids. Intensity of the radioactivity associated with the [ 32 P]PA was quantified using the Scion Image program and data were expressed as percentage of control (untreated cells).
Reactive Oxygen Species Measurement by 2 0 -7 0 -Dichlorofluorescin Diacetate Fluorescence Formation of ROS in BLMVECs in 35-mm dishes (5 Â 10 5 cells/dish) was determined by 2 0 -7 0 -dichlorofluorescin diacetate (DCFDA) fluorescence in cells preloaded with 10 mmol/L DCFDA for 30 minutes in complete MEM at 37 C in a 95% air and 5% CO 2 environment prior to experimental treatments, according to our previously published procedure. 22 ,23 2 0 -7 0 -Dichlorofluorescin diacetate fluorescence as an index of intracellular ROS generation was visualized under Olympus fluorescence microscope at Â50 magnification with excitation and emission set at 490 and 530 nm, respectively. Intracellular ROS formation was quantified by measuring DCFDA fluorescence in lysates of cells on a Bio-Tex ELx808 fluorescent plate reader set at 490 nm excitation and 530 nm emission, using appropriate blanks. 22, 23 The extent of intracellular ROS formation was expressed as the arbitrary fluorescence units.
Glutathione Determination
Intracellular soluble thiol (GSH) levels were determined using the GSH-Glo GSH assay kit. Bovine lung microvascular ECs grown up to 90% confluence in 96 well plates were treated with MEM alone or MEM containing desired concentrations of bleomycin for 12 hours under a humidified 95% air and 5% CO 2 atmosphere. Following incubation, intracellular GSH levels were determined according to the manufacturer's recommendations (Promega Corp, Madison, Wisconsin).
Immunofluorescence Microscopy
Bovine lung microvascular ECs cultured on sterile coverslips (Harvard Apparatus, 22 mm 2 ) in 35-mm sterile dishes at a density of 10 4 cells/dish were treated with MEM alone and MEM containing bleomycin for 12 hours under a humidified atmosphere of 95% air and 5% CO 2 at 37 C. Following the experimental treatments, cells were incubated for 12 hours at room temperature with rabbit primary anti-4HNE antibody (1:200 dilution, v/v) to detect lipid peroxidation. After the primary antibody treatment, cells were incubated with the secondary antirabbit AlexaFluor 488-conjugated antibody (1:100 dilution, vol/vol), for 1 hour at room temperature. The coverslips with cells were then mounted on a glass slide with the antifade mounting medium, Fluoromount-G, viewed with Ziess Confocal microscope at a magnification of Â60, pictures were captured digitally, and the extent of 4-HNE formation was determined from the fluorescence intensity using the Scion Image software. 6 Cytotoxicity Assay
In the current study, we utilized 3 different cytotoxicity assay viz (i) cell morphology examination, which demonstrates the loss of cell shape, necrosis, and cytoskeletal alterations (attachment) due to toxic effects; (ii) LDH leak assay, which reveals the plasma membrane damage and leak of cellular macromolecules in response to the toxic insult; and (iii) MTT reduction assay, which demonstrates the mitochondrial dysfunction due to their inability to reduce MTT during toxic insult.
Morphology Assay of Cytotoxicity
Morphological alterations in BLMVECs cultured in 35-mm dishes up to 70% confluence, following experimental treatments, were examined as an index of cytotoxicity according to our previously published methods. 24 Images of cell morphology were digitally captured with the Olympus microscope at Â20 magnification.
Lactate Dehydrogenase Release Assay of Cytotoxicity
Cytotoxicity in ECs was determined by assaying the extent of release of LDH from cells according to our previously published method. 24 At the end of treatment, the medium was collected and the LDH released into the medium was determined spectrophotometrically using the commercial LDH assay kit according to the manufacturer's recommendations (Sigma Chemical Co).
3-[4,5-Dimethylthiazol-2-yl]-2, 5-Diphenyl Tetrazolium Bromide Reduction Assay of Cytotoxicity
Cytotoxicity in ECs was determined by assaying the extent of reduction of MTT in intact cells using the commercial MTT reduction assay kit. At the end of the experimental treatments, MTT solution (10% by vol in MEM) was added and the cells were incubated for 3 hours, following which MTT solvent was added in an amount equal to the original culture volume. Absorbance of the reduced MTT was determined spectrophotometrically according to the manufacturer's recommendations (Sigma Chemical Co).
Uptake and Distribution of PA
Bovine lung microvascular ECs cultured on sterile coverslips (Harvard Apparatus, 22 mm 2 ) in 35-mm sterile dishes, at a density of 10 4 cells/dish, were treated with MEM alone and MEM containing fluorescent C 6:0-18:1 NBD-PA (5 mmol/L) for 24 hours under a humidified atmosphere of 95% air and 5% CO 2 at 37 C. At the end of the incubation period, cells attached to coverslips were washed with 1Â PBS, fixed with 3.7% of paraformaldehyde for 10 minutes, permeabilized with 0.25% Triton X-100 in Tris buffer saline Tween-20 (TBST) containing 0.01% Tween-20 for 5 minutes, then blocked for 30 minutes with 1% BSA in 0.01% TBST, and incubated for 5 minutes at room temperature with 1% (v/v) DAPI in PBS to visualize the nuclei. The coverslips with cells were then mounted on a glass slide with the antifade mounting medium, Fluoromount-G, viewed under Ziess Confocal fluorescence microscope at a magnification of Â60, and pictures were captured digitally.
Protein Determination
Protein was determined by the bicinchoninic acid (BCA) protein assay (Thermo Scientific, Rockford, Illinois).
Statistical Analysis
All experiments were done in triplicate. Data were expressed as mean + standard deviation (SD). Statistical analysis was carried out by analysis of variance (ANOVA) using SigmaStat (Jandel Scientific, San Rafael, California). The level of statistical significance was taken as P < .05.
Results

Bleomycin Induces PLD Activation in Dose-and Time-dependent Fashion in ECs
Here, we conducted studies to (i) determine whether bleomycin would increase PLD activation in lung ECs and (ii) compare the bleomycin-induced PLD activation in 2 different established lung EC models such as BLMVECs (of bovine origin) and HLMVECs (of human origin). Bleomycin, in a dosedependent manner (5, 10, and 100 mg), at 4 and 12 hours of incubation, induced significant activation of PLD ([ 32 P]PBt formation) in BLMVECs as compared with the vehicletreated control cells (2-, 2-, and 3-fold for 4 hours and 5-, 6-, and 12-fold for 12 hours at 5, 10, and 100 mg, respectively; Figure 1A) . Treatment of ECs with bleomycin (5 mg) for 4, 8, 12, and 24 h induced significant increases (2-, 3-, 4-, and 3-fold) in the activation of PLD as compared with that in the cells exposed to the MEM alone ( Figure 1B) . Bleomycin, in a dose-dependent manner (5, 10, and 100 mg), at 8 and 12 hours of incubation, induced significant activation of PLD in HLMVECs as compared with that in the vehicle-treated control cells (2-, 2-, and 3-fold for 8 hours and 2-, 3-, and 3-fold for 12 hours at 5, 10, and 100 mg, respectively; Figure 1C ). These results revealed that bleomycin induced PLD activation in dose-and time-dependent manner in both BLMVECs and HLMVECs. These results demonstrated that bleomycin induced PLD activation in chosen EC systems including those of bovine (BLMVECs) and human (HLMVECs) origins. However, subsequent experiments in the current study were conducted using the ECs of bovine origin (BLMVECs).
Thiol Protectants Attenuate Bleomycin-Induced PLD Activation in ECs
Altered thiol redox has been shown to activate PLD in ECs. Therefore, to establish the role of thiols in bleomycininduced PLD activation in ECs, here, the effects of well-established thiol protective agents (N-acetyl-L-cysteine [NAC] and Dithiothreitol [DTT]) were investigated on PLD ([ 32 P]PBt formation) activation induced by bleomycin. Cells were pretreated for 2 hours with MEM alone or MEM containing the chosen thiol protectant (0.5, 1, and 5 mmol/L) and then cotreated for 12 hours with bleomycin (5 mg) and the chosen thiol protectant. NAC, a widely used thiol protectant and antioxidant, caused effective and significant attenuation of bleomycininduced PLD activation in ECs (22%, 70%, and 97% of inhibition for concentrations of 0.5, 1, and 5 mmol/L, respectively; Figure  2A ). DTT, a sulfhydryl protective agent, also offered effective and significant attenuation of the bleomycin-induced PLD activation in ECs (43%, 67%, and 65% of inhibition at concentrations of 0.5, 1, and 5 mmol/L, respectively; Figure 2B ). These results revealed that thiol protectants effectively attenuated the bleomycin-induced PLD activation in ECs, further suggesting the involvement of cellular thiol redox status in the bleomycininduced activation of PLD in ECs. 
Heavy Metal Chelators Attenuate Bleomycin-Induced PLD Activation in ECs
Oxidative stress and ROS production have been shown to activate PLD in ECs. Among heavy metals, particularly Fe 2þ has been shown to be involved in the generation of ROS especially through Fenton-type reactions. 25 Bleomycin complexes with iron to become an active drug. 26 Therefore, to establish the role of iron-mediated oxidative stress in bleomycin-induced PLD activation in ECs, here, the effects of well-established heavy Figure 3A and B). DMSA, a heavy metal chelator and a thiol redox stabilizer, also offered effective and significant attenuation of the bleomycin-induced PLD activation in ECs (39%, 64%, and 64% of inhibition at concentrations of 0.5, 1, and 5 mmol/L, respectively; Figure 3C ). These results revealed that heavy metal chelators, especially Fe 2þ -specific chelators, effectively attenuated the bleomycin-induced PLD activation in ECs, further suggesting the involvement of ROS production in the bleomycin-induced enzyme activation in ECs.
Antioxidants Attenuate Bleomycin-Induced PLD Activation in ECs
Oxidative stress, ROS production, and altered thiol redox has been shown to activate PLD in ECs. 1, 2 Moreover, bleomycin is established as an oxidant drug. We also found earlier in this study that heavy metal chelators and thiol protectants effectively and significantly attenuated the bleomycin-induced PLD activation in ECs. Therefore, in order to establish the role of oxidative stress in the bleomycin-induced PLD activation in ECs, here, the effects of established antioxidants (Pyrrolidine Dithiocarbamate on the PLD activation induced by bleomycin. Cells were pretreated for 2 hours with MEM alone or MEM containing the chosen antioxidant (0.5, 1, and 5 mmol/L of PDTC, 500 mmol/L of propyl gallate and vitamin C, and 20 mmol/L of MnTBAP) and then co-treated for 12 hours with bleomycin (5 mg) and the chosen antioxidant. PDTC caused effective and significant attenuation of the bleomycin-induced PLD activation in ECs (25%, 49%, and 72% of inhibition at 0.5, 1, and 5 mmol/L, respectively; Figure 4A ). Propyl gallate, a phenolic antioxidant and vitamin C, also offered effective and significant attenuation of the bleomycininduced PLD activation in ECs (49% and 46%, respectively; Figure 4B and C). MnTBAP, a superoxide scavenger, also offered effective and significant attenuation of the bleomycin-induced PLD activation in ECs (21%; Figure  4D ). These results revealed that antioxidants effectively attenuated the bleomycin-induced PLD activation in ECs, further suggesting the involvement of ROS in the bleomycin-induced enzyme activation in ECs.
Lipid Peroxidation Inhibitors Attenuate Bleomycin-Induced PLD Activation in ECs
Oxidative stress and ROS production have been shown to induce lipid peroxidation in ECs. 1 respectively; Figure 5B ). These results revealed that lipid peroxidation-inhibiting antioxidants effectively attenuated the bleomycin-induced PLD activation in ECs, further suggesting the involvement of lipid peroxidation in the bleomycininduced activation of PLD in ECs.
Bleomycin Induces ROS Generation and Depletes GSH in ECs
The pharmacological action of bleomycin has been attributed to its ability to induce ROS formation. 26 Earlier in this study, we showed that the bleomycin-induced PLD activation was attenuated by antioxidants, and therefore here we hypothesized that bleomycin would induce the intracellular ROS formation in ECs. Therefore, here we investigated the ability of bleomycin to induce the intracellular ROS formation in BLMVECs by determining the DCFDA fluorescence. Bleomycin, in a dose-dependent manner (5, 10, and 100 mg), at 1 hour of treatment, induced significant ROS formation in BLMVECs as compared with that in the vehicle-treated control cells ( Figure  6A) . Bleomycin, at 0.5 hour of treatment, effectively induced the ROS formation in BLMVECs as compared with that in the control untreated cells (1.5-, 1.8-, and 2-fold at 5, 10, and 100 mg, respectively; Figure 6B ). Hence, these results demonstrated that bleomycin induced the intracellular ROS formation in ECs. Earlier in this study, we showed that thiol protectants Each micrograph is a representative picture obtained from 3 independent experiments conducted under identical conditions. Bovine lung microvascular ECs (1 Â 10 5 cells/96 well plates) were subjected to treatment with MEM alone or MEM containing bleomycin (5, 10, and 100 mg) for attenuated the bleomycin-induced PLD activation in ECs. Therefore, here we hypothesized that bleomycin would cause the depletion of intracellular GSH. To test this postulate, intracellular soluble thiols (GSH) were measured. Bleomycin in a dose-dependent manner induced significant depletion of cellular GSH in BLMVECs at 12 hours of exposure as compared with the same in the vehicle-treated control cells (60%, 57%, and 45% of decrease at 5, 10, and 100 mg, respectively; Figure  6C ). These results demonstrated that bleomycin caused the loss of intracellular GSH leading to the altered thiol redox status in BLMVECs.
Bleomycin Induces Lipid Peroxidation in ECs
Earlier in this study, we showed that bleomycin caused the production of ROS in ECs. Reactive oxygen species is known to cause lipid peroxidation of polyunsaturated fatty acids and produce highly reactive carbonyls such as 4-HNE. 27 To observe whether bleomycin would induce lipid peroxidation in ECs, cells were treated with bleomycin for 12 hours, fixed, and stained with the anti-4-HNE antibody. Using confocal microscopy, bleomycin was found to induce the formation of 4-HNE (as an index of lipid peroxidation) in a dose-dependant manner (6-, 6-, and 10-fold increase at 5, 10, and 100 mg of bleomycin, respectively; Figure 7A and B).
Bleomycin Induces Morphological Alterations Which are Protected by PLD-Specific Inhibitor (FIPI) in ECs
As PLD is a lipid-signaling enzyme and plays an important role in cellular functions through the generation of bioactive lipid signal mediators, here we investigated the effects of bleomycin on the cell morphology as an index of disruption of cellular structure and cytotoxicity. Bovine lung microvascular ECs were treated with bleomycin (5, 10, and 100 mg) for 4, 8, 12, and 24 hours and then subjected to cell morphology examination by light microscopy. Bleomycin, in a time-and dosedependant manner, caused morphological alterations ( Figure  8A) . The results revealed that bleomycin at a dose of 5 mg caused initiation of morphological alterations at 4 hours of treatment, which were prominent at 12 hours of treatment in BLMVECs. In order to determine that PLD activation would be involved in the bleomycin-induced cell morphology alterations (cytotoxicity), we treated the BLMVECs with the PLDspecific inhibitor, FIPI, to inhibit PLD activity and investigated the bleomycin-induced cell morphological alterations. Cells were pretreated with FIPI (1 mmol/L) for 12 hours to ensure the optimal uptake of the inhibitor and co-treated with bleomycin (5 mg) for 4, 8, 12 and 24 hours, following which their morphology was examined microscopically. 5-Fluoro-2-indolyl des-chlorohalopemide significantly attenuated the bleomycin-induced cell morphological alterations at all time points, suggesting PLD activation in the bleomycin-induced cytotoxic morphological alterations in BLMVECs ( Figure 8B ).
Bleomycin Induces Cytotoxicity in ECs
As bleomycin in this study was shown to cause morphological alterations in ECs, here, another measure of cytotoxicity, the release of LDH by the BLMVECs exposed to bleomycin was determined. Bleomycin induced the release of LDH in a doseand time-dependant fashion. Bleomycin (5, 10, and 100 mg) caused significant LDH release (0.2-, 0.2-, and 1-fold, 2-, 2-, and 3-fold, and 2-, 2-, and 3-fold increase at 8, 12, and 24 hours, respectively) as compared with the same in the control untreated cells (Figure 9A, B, and C) . These results indicated that bleomycin induced cytotoxicity in ECs as evidenced by LDH release.
PLD-Specific Inhibitor, FIPI, Protects Against Bleomycin-Induced Cytotoxicity and Attenuates Bleomycin-Induced PLD Activation in ECs
As the PA generated from PC through PLD action has been implicated in many physiological responses, here, we investigated whether the cytotoxic effects of bleomycin were caused by the PLD-generated PA in ECs. Therefore, we investigated whether the PLD-specific inhibitor, FIPI, would offer protection against the bleomycin-induced cytotoxicity as assayed by the LDH release from the cells. ECs were pretreated with FIPI (250, 500, and 1000 nmol/L) for 12 hours, prior to exposure to bleomycin (5 mg) for 12 hours. 5-Fluoro-2-indolyl des-chlorohalopemide (250, 500, and 1000 nmol/L) significantly caused dose-dependent attenuation of the bleomycin-induced LDH release (23%, 36%, and 45%) from BLMVECs ( Figure 10A ). These results suggested the role of PLD and PLD-generated PA in the bleomycin-induced cytotoxicity in ECs. We speculated that the cytotoxic effects of bleomycin were mediated by the PLD-generated PA. To test this premise, we wanted to inhibit the PLD activity using the novel PLD inhibitor, FIPI. 5, 21 Bovine lung microvascular ECs were pretreated with FIPI (250, 500, and 1000 nmol/L) for 12 hours while they were being labeled with [ 32 P]orthophospate to ensure the effective uptake of the inhibitor. Following that the ECs were then co-treated with FIPI and bleomycin (5 mg) for 12 hours. The results revealed that FIPI significantly attenuated the bleomycin-induced PLD activation (25%, 42%, and 68% at 250, 500, and 1000 nmol/ L, respectively). 5-Fluoro-2-indolyl des-chlorohalopemide was also found to inhibit the basal normal PLD activity (27%, 47%, and 62% at 250, 500, and 1000 nmol/L, respectively; Figure 10B ). 5-Fluoro-2-indolyl des-chlorohalopemide by itself was not observed to cause any adverse or cytotoxic effects in BLMVEC as revealed from the cell morphology examination ( Figure 8B ) and LDH release assay ( Figure 10A ). Therefore, these results clearly demonstrated that FIPI caused effective inhibition of the bleomycin-induced activation of PLD in ECs in a dosedependent manner.
Bleomycin Induces PA Formation in ECs
As PA is the lipid signal mediator generated by PLD action on cellular membrane phospholipids, here, we investigated the bleomycin-induced formation of PA in BLMVECs. Bleomycin (5, 10, and 100 mg), following 12 hours of treatment of cells induced significant formation of PA in BLMVECs as compared with the same in the control untreated cells (125%, 122%, and 133% of increase at 5, 10, and 100 mg, respectively; Figure 11A and B). Upon increasing the dose up to 100 mg, bleomycin did not appear to alter/enhance the extent of PA formation that was observed in BLMVECs treated with the lowest dose of bleomycin (5 mg). These results revealed that bleomycin induced the formation of PA in BLMVECs.
Phosphatidic Acid Induces Cytotoxicity in ECs
As shown earlier in this study, the PLD-generated PA was associated with cytotoxicity, here we investigated whether exogenously added PA would cause cytotoxicity in BLMVECs. Lactate dehydrogenase cytotoxicity release and MTT reduction by cells treated with varying concentrations of 1,2-dilinoleoyl-sn-glycero-3-phosphate (C 18:2 PA), and 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphate (C 16:0-18:1 PA) were determined as the indices of cytotoxicity. C 18:2 PA (1, 10, and 25 mg/mL) caused enhanced extent of LDH release by 234%, 167%, and 309%, respectively, at 12 hours of treatment of BLMVECs as compared to the same in the control untreated cells ( Figure 12A ). C 16:0-18:1 PA (1, 5, and 10 mg/mL) caused significant decrease in MTT reduction by 7%, 43%, and 40%, respectively, at 12 hours of treatment of BLMVECs, as compared to the same in the control untreated cells ( Figure 12B) . These results revealed that exogenous PA caused cytotoxicity in ECs.
Phosphatidic Acid is Taken up and Localized in ECs
Earlier in this study, we showed that bleomycin caused the production of PA and exogenously added PA caused cytotoxicity in ECs. To observe the intracellular targets of PA, BLMVECs were treated with fluorescent C 6:0-18:1 NBD-PA (5 mmol/L) for 24 hours, fixed, and stained with nuclear-specific stain, DAPI. Using the confocal fluorescence microscopy, fluorescent C 6:0-18:1 NBD-PA, cellular uptake was noticed and localized heavily in the cytosol and the perinuclear regions with scanty localization in the nucleus of BLMVECs. Control cells treated with vehicle alone showed no fluorescence ( Figure 13A) , as opposed to the cells treated with the fluorescent C 6:0-18:1 NBD-PA exhibiting intracellular distribution of PA ( Figure 13B, C, and D) . These results clearly demonstrated that the lipid signal mediator PA exhibited intracellular localization at targeted specific sites.
Discussion
The results of the current study revealed that bleomycin at mg doses induced the activation of PLD, which was attenuated by antioxidants, thiol protectants, and iron chelators, suggesting the upstream role of oxidants and altered redox signaling in the activation of PLD in BLMVECs. This was further confirmed by the enhanced generation of ROS and decrease in thiol levels upon treatment of BLMVECs with bleomycin. Phospholipase D-specific inhibitor, FIPI, caused complete inhibition of the bleomycin-induced activation of PLD and also offered protection against the cytotoxic effects of bleomycin in BLMVECs. Furthermore, the current study also revealed that bleomycin caused enhanced formation of PA and exogenous PA treatment resulted in cytotoxicity in BLMVECs. Using the fluorescent NBD-PA, we also demonstrated the uptake and subcellular localization of PA in BLMVECs. Taken together, these results demonstrated the role of PLD-generated PA in the bleomycin-induced lung microvascular EC damage (Figure 14) . Phospholipases are enzymes capable of hydrolyzing the membrane phospholipids at specific sites and generating bioactive lipid second messengers, which may play vital roles in cell signaling. 28 Phospholipase D is one such lipid-signaling enzyme ubiquitously present in all mammalian cells that preferentially hydrolyzes phosphatidylcholine (PC), thus generating PA and choline. 29 Phosphatidic acid is further metabolized to either DAG by phosphatidate phosphohydrolase (lipid phosphate phosphohydrolase) or LPA by phospholipase A 1 /A 2 . [30] [31] [32] Agonist-mediated activation of PLD plays a pivotal role in signal transduction in mammalian cells. 33, 34 Several functions, including the promotion of mitogenesis in fibroblasts, stimulation of oxidative stress in neutrophils, increase of intracellular calcium, activation of protein kinases, and phospholipases have been attributed to the signaling actions of PA and LPA. 29 Two major forms of PLD, hPLD 1 and hPLD 2 have been cloned in mammalian cells. [35] [36] [37] [38] Even though the 2 isoforms of PLD catalyze hydrolysis of PC to PA, they are selectively activated by various cofactors such as Arf, Rho, Cdc42, and detergents. 39, 40 Phosphatidylinositol 4,5-bisphosphate (PIP 2 ), a lipid mediator, activates both hPLD 1 and hPLD 2 in cell-free preparations. The results of the current work showed that bleomycin activated PLD in the BLMVECs, which resulted in the enhanced generation of the lipid signal mediator, PA, and this could be possible through the actions of both PLD 1 and PLD 2 isoforms as the presence of both the isoforms in ECs has been detected. 22 However, the relative activity of both the isoforms in the bleomycin-induced formation of PA is yet to be determined. Earlier studies have shown that oxidants and ROS such as hydrogen peroxide, fatty acid hydroperoxide, and 4-hydroxynonenal simulate PLD in vascular ECs, smooth muscle cells, and fibroblasts. [41] [42] [43] [44] [45] The ROS-mediated PLD activation is attenuated by tyrosine kinase inhibitors in ECs, suggesting a role for protein tyrosine phosphorylation in PLD activation. 22 In addition to tyrosine kinase inhibitors, PLD activation by oxidants is also attenuated by antioxidants, indicating redox regulation of PLD. 2 Recently, we have reported that mercury activates PLD in the vascular ECs through thiol redox alteration and generation of ROS. 23 Antioxidants including the thiol protectants have been shown to attenuate the pro-oxidantinduced activation of PLD in lung microvascular ECs, suggesting the role of ROS and thiol redox in the enzyme activation. 1 Along these lines, the results of the current study also revealed that the bleomycin-induced PLD activation was regulated by the ROS, thiol redox (GSH) perturbation, and lipid peroxidation (4-HNE formation) in BLMVECs. The current study also demonstrated the involvement of oxidant-induced and thiol-regulated signaling in the bleomycin-induced activation of PLD, generation of PA, and cytotoxicity in the lung microvascular ECs. However, the regulation of PLD activation by different stimuli is complex and involves changes in intracellular Ca 2þ , PKC, heterotrimeric G proteins, small molecular weight G proteins, and protein tyrosine kinases/protein tyrosine phosphatases. 6, 22, 46 The precise signaling node responsible for mediating the oxidant-induced and thiol-regulated activation of PLD caused by bleomycin in BLMVECs needs to be established. Bleomycin is an oxidant drug and has been commonly used to induce pulmonary fibrosis in animal models. 47, 48 Bleomycin is well known for its action of inducing oxidative stress and redox alteration both in vivo and in vitro. 19, 49 Iron binds to bleomycin to generate oxidants which damage DNA. 50 The bleomycin-induced DNA damage is protected by iron chelators such as EDTA. 51 Oxidation of extracellular cysteine and alteration of redox state in lung, induction of apoptosis and senescence in lung cells, and disruption of iron homeostasis due to bleomycin exposure have been noticed in relation to the bleomycin-induced pulmonary fibrosis. 26, 49, 52, 53 Formation and role of lipid-derived free radicals have been observed in bleomycin-induced lung injury, indicating the role of lipid peroxidation in the pulmonary toxicity of bleomycin. 54 Free radical quencher and lipid peroxidation chain-breaking antioxidant such as a-tocopherol has also been reported to protect against the bleomycin-induced lung injury, suggesting the role of lipid peroxidation and lipid radicals in the pulmonary toxicity of the drug. 55 Resveratrol, a phytochemical and antioxidant, has been shown to alleviate the bleomycin-induced lung injury in rats in vivo. 56 The thiol protectant, NAC, and the iron chelator, deferoxamine, have been observed to attenuate the bleomycin-induced oxidative stress and lung injury. 57 Thus, these reports support our current findings that bleomycin induced oxidative stress, altered thiol redox status, induced lipid peroxidation, activated PLD, and caused cytotoxicity in a redox-dependent pathway in BLMVECs. Our current study also provided evidence in favor of the protection of the bleomycin-induced adverse effects in the ECs offered by antioxidants, thiol protectants, and iron chelator.
One of the key findings of the current study was the role of PLD-generated PA in the cytotoxicity of bleomycin in Figure 14 . Proposed mechanism. Schematic representation of bleomycin-induced PLD activation and generation of lipid signal mediator, PA, and the subsequent lung endothelial damage. PLD indicates phospholipase D; PA, phosphatidic acid.
BLMVECs. This was further confirmed by the use of the novel PLD-specific inhibitor, FIPI, 5, 21 which not only completely inhibited the bleomycin-induced activation of PLD but also attenuated the cytotoxicity (altered cell morphology and LDH release) of bleomycin in the lung microvascular ECs. This observation further established a link between the upstream activation of PLD and downstream cytotoxicity exerted by bleomycin in BLMVECs, thus offering first evidence in favor of the role of the PLD-generated bioactive lipid mediator, PA therein. As the PLD-generated PA can further undergo enzymatic conversion into DAG and/or LPA, it was not clear whether the cytotoxicity-inducing bioactive lipid, generated by PLD through bleomycin action, was PA, DAG, LPA, or combination of those. Phospholipase D-generated PA has been identified as the precursor of LPA formation through the actions of PLA 1 /PLA 2 . 58, 59 Lysophosphatidic acid receptors, a member of the G protein-coupled receptors, have been shown to be involved in several physiological and pathophysiological states. 58, 60 Lysophosphatidic acid receptors 1 and 2 have been identified to play roles in the regulation of vascular injury. 61 The role of LPA receptor 1 linking pulmonary fibrosis to lung injury toward causing fibroblast recruitment and vascular leak in the bleomycin mouse model of pulmonary fibrosis has been unequivocally elucidated. 62 Nevertheless, the sources of LPA in these studies have not been identified at least in the bleomycin pulmonary fibrosis model. On the other hand, the current study indicated PLD as a possible source of PA that could be converted into LPA, another potent bioactive lipid mediator, which could be responsible for the observed bleomycininduced vascular EC damage. Also, it should be emphasized that PLD-derived PA could have also exerted its cellular effects through PA-dependent or DAG-mediated signaling cascades.
The bleomycin-induced cytotoxicity in BLMVECs as observed in the current study might be due to both PA and other PA-derived signal mediators such as LPA and DAG. Nevertheless, our current study demonstrated that when BLMVECs were treated with exogenous PA, (i) the lipid was taken up and localized in cellular compartments including cytosol, perinuclear, and nuclear region ( Figure 13 ) and (ii) induced cytotoxicity. This observation reinforced the role of PA in causing cytotoxicity of bleomycin through the activation of PLD in ECs.
Overall, the current study offered a novel signaling pathway of bleomycin-induced lung microvascular EC damage, involving the oxidative stress-mediated and thiol redox-regulated PLD activation and generation of the bioactive lipid mediator, PA ( Figure 14 ). Furthermore, the findings of the current study also identified PLD as a possible target for the therapeutic intervention of IPF.
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